INTRODUCTION {#s1}
============

Several recent studies of populations of different ancestral continent of origin (ACOO) have identified ACOO-specific gene expression differences. Because the sets of genes identified in these studies are largely non-overlapping, the biological interpretation of these results is challenging ([@DDP330C1]--[@DDP330C6]). Given the importance to health disparities of such studies, we have undertaken an integrative approach to determine whether indeed there is a consistent difference. We have also added a new study sample to further validate our findings. Cross-population expression studies are fraught with the well-known variability in the biology as well as the difficulties in comparing transcriptome-wide measures from different platforms ([@DDP330C7],[@DDP330C8]) and the increasingly documented intrinsic biases of expression patterns of immortalized cell lines ([@DDP330C6]). Technical bias may affect many genes in concert, thus causing spurious correlations in clinical data sets and false associations between genes and clinical variables ([@DDP330C9]). The study of the transcriptome in groups with different ACOO is particularly problematic in that most of these studies are performed on Epstein--Barr virus (EBV) immortalized cell lines. Specifically, the International HapMap Project harvested peripheral blood lymphoblasts from the homogenous Yoruba tribe from Ibadan Nigeria (YRI) and then transformed them into immortalized cells *in vitro* using the EBV. This is of potential additional relevance, as the YRI population is one of the sub-Saharan populations known to suffer from an endemic childhood cancer Burkitt lymphoma (BL), caused by the EBV that environmentally saturates sub-Saharan Africa ([@DDP330C10]--[@DDP330C13]). In contrast, the CEU \[homogeneous US residents with northern and western European ancestry (HapMap samples)\] population as well as other populations with European ancestry has to date no reported predisposition or population-specific susceptibility to EBV infection. This raises the question of the degree to which the reported expression differences are due to laboratory technique, measurement platform difference, laboratory-specific variation in EBV-driven cell immortalization, or COO-specific responses to EBV infection and immortalization. To explore this question, we filtered samples and genes to accentuate population stratification between CEU and YRI trios. Our guiding principle was to select for samples and genes with the highest consistency within ACOO and the least overlap across ACOO. Our approach is outlined in Figure [1](#DDP330F1){ref-type="fig"}. We analyzed four independent recent studies, three of which were conducted on immortalized cell lines previously published ([@DDP330C5],[@DDP330C14],[@DDP330C15]), to find the reproducible differences by ACOO across two expression array platforms (Affymetrix and Illumina), and a fourth analysis was performed on an expression experiment of primary lymphoid cells from African Americans (AAs) and Caucasians (CAs) ([@DDP330C16]). Further description of the experiments, type of array platforms and genes analyzed are listed in [Supplementary Material, Table S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp330/DC1). To reduce noise from the varied measurement platforms and laboratory-specific technique, this analysis was intentionally driven to high specificity at the cost of sensitivity ([@DDP330C9]) by the filtering process, as described. Our analysis identified an 'immortalization network' consisting of 40 genes, of which 24 genes are differentially expressed between the CEU and YRI populations. Furthermore, one of these genes, Werner syndrome helicase (WRN), is significantly correlated with EBV titer. Subsequently, we relaxed the original aggressive filtering of the data and found the large majority of the immortalization network\'s genes were differentially expressed across ACOO. Moreover, we identified a *cis* eQTL in gene POLR1A in the network with respect to ACOO.

![Analytic flow of the expression analysis of ACOO. Shaded boxes at the top represent independent data sets of gene expression profiling. The topmost three boxes are three experiments by different investigators on two expression profiling platforms measuring expression in the immortalized lymphoblasts of the YRI and CEU HapMap individuals. The fourth data set is measured on a group of children (CA and AA) who served as controls in an unrelated (autism) study. These cells in this population were not immortalized prior to measurement. Eighty probe sets were measured as significantly differentially expressed across the three immortalized cell data sets. Of those, 66 were also differentially expressed in non-immortalized data set and the subsequent analysis focused on those 14 probe sets that were only differentially expressed in the immortalized cells. Twelve of those 14 probe sets were mapped to genes in IPA, and a network (dubbed the COO Immortalization Network) of 40 genes was automatically constructed. This network was then assessed against the three original expression data sets in two ways. First, one gene was identified as having a significant eQTL based on the associated HapMap SNP data. Second, additional 11 genes from the immortalization network were differentially expressed across all three data sets in addition to the original 12 found (through a much more stringent filter).](ddp33001){#DDP330F1}

RESULTS {#s2}
=======

Identification of initial COO differential expression {#s2a}
-----------------------------------------------------

We started the analysis with the reproducibility of the COO-specific differences in the first study ([@DDP330C4]), across two trios (CEU and YRI) divided into four populations: HapMap parents (YRI~p~ and CEU~p~) and separately HapMap children (YRI~c~ and CEU~c~). We selected those genes that were expressed most consistently within the YRI and separately CEU populations, respectively, and then identified those of the intersecting set that were significantly differentially expressed. The intersection of the number of consistently expressed genes within COO across both populations differed for the parents (*n* = 1043) when compared with their children (*n* = 568). The shared set of genes that were highly consistently expressed in both parental and child populations and that also were significantly differentially expressed after Bonferroni correction numbered 228 ([Supplementary Material, Table S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp330/DC1)). The biological functions program significantly enriched \[as per the Ingenuity IPA program ([@DDP330C17])\] in the differentially expressed genes included processing and splicing of mRNA, immortalization of cells, transcription and expression of DNA, synthesis and metabolism of proteins, processing and modification of rRNA, receptor-mediated endocytosis, transport and catabolism of proteins, colony formation, activation of HIV type 1, ubiquitination and cholangiocarcinoma (data not shown). Of the 228 genes differentially expressed across ACOO, the top 20 genes most correlated with WRN, using Pearson correlation, were identified and highlighted with an '\*' in [Supplementary Material, Table S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp330/DC1). Of note, the viral titer (courtesy David Altshuler, see Materials and Methods) correlated significantly with WRN gene expression across the filtered CEU and YRI samples from Stranger *et al*. ([@DDP330C5]) with an *R*^2^ = 0.69 and regression-significant *P* = \<2.2 × 10^−16^ (Fig. [2](#DDP330F2){ref-type="fig"}A). Separately, the children\'s EBV titer correlated with WRN expression with an *R*^2^ of 0.86 and *P*-value of 2.89 × 10^−13^, and the parents EBV titer correlated with WRN expression with an *R*^2^ of 0.70 and *P*-value of 1.18 × 10^−13^ (data not shown). The distribution of WRN values is much higher than the average expression of genes in the genome across all samples, which is consistent with previous reports of WRN having high levels of expression in immortalized cells. The 20 genes closely correlated with WRN also have higher mean expression across the CEU and YRI populations when compared with WRN and all the transcripts measured on the arrays (Fig. [2](#DDP330F2){ref-type="fig"}B).

![(**A**) Correlation of WRN to relative EBV titer across the filtered CEU and YRI samples and (**B**) the distribution of non-normalized WRN values and the mean values of the 20 genes across the CEU and YRI populations and for all the transcripts measured on the arrays.](ddp33002){#DDP330F2}

Cross platform validation of differentially expressed genes {#s2b}
-----------------------------------------------------------

We conducted further analyses on an additional independent CEU and YRI population\'s transcriptome study. This study was performed on the Affymetrix GeneChip Human Genome U133 Array Set HG-U133A ([@DDP330C15]). Of the 228 genes significantly different on the Illumina platform between CEU and YRI, there were 99 probe sets corresponding to the same genes significantly different on the Affymetrix platform. Of these 99 probe sets, 21 were removed because the differential expression was discordant (down for the YRI population on the Illumina platform but up regulated compared to the CEU on the Affymetrix platform) leaving 78 probe sets for further analyses (Table [1](#DDP330TB1){ref-type="table"}). WRN was also among the genes that were significantly different on the Affymetrix HG-U133A platform. In a third, but much smaller, data set, we applied the aforementioned filtering process on only eight CEU and eight YRI founder males from the Affymetrix Human Focus Array and only one gene, WRN, was found to be significantly different between CEU and YRI samples. That is, WRN is significantly differentially expressed in three independent studies ([@DDP330C4],[@DDP330C14],[@DDP330C15]). The top disease and disorders (as per the Ingenuity IPA program) enriched were viral function, connective tissue disorders (immortalization), cancer, cardiovascular disease and endocrine system disorders. WRN is among the genes in each of the top three enriched categories. The biological functions significantly enriched in the differentially expressed genes included processing and splicing of mRNA, cross-link repair of DNA, viral transactivation, immortalization of cells, transcription and expression of DNA, cell division, colony formation, contact growth inhibition, apoptosis, cell death, synthesis of proteins, gastric carcinoma (Table [2](#DDP330TB2){ref-type="table"}). Additionally, we performed linear regression analyses to determine the squared Pearson correlation coefficients (*R*^2^) and *p-*values of the 20 genes most correlated with WRN (dependent variable) mRNA expression in a pairwise manner out of the 78 probe sets cross-platform validated for ACOO differential expression. We used an *R*^2^ cutoff of 0.7. Consequently, the top 20 correlated probe sets have an *R*^2^ between 0.69 and 0.84, and *P*-values \<2.2 × 10^−16^ as described in Table [3](#DDP330TB3){ref-type="table"}. Sixteen (80%) of the 20 top correlated genes grouped with WRN into one biological functions network associated with *gene expression*, *infection mechanism* and *cancer* with an enrichment *P-*value of 1.0 × 10^−47^. Seven of the top 20 genes are members of the final 12 gene set that comprised the immortalization network. We created an annotated network of these 20 genes entitled the *'Viral infection network*', with the transcription factors MYC and P53 serving as the central hubs of this network (Fig. [3](#DDP330F3){ref-type="fig"}).

![Of the 78 probe sets cross-platform validated with ACOO differential expression, 16 (80%) of the top 20 WRN-correlated genes (*R*^2^ between 0.69 and 0.84) grouped with WRN into one biological functions network associated *with gene expression*, *infection mechanism* and *cancer* with an enrichment *P*-value of 1.0 × 10^−47^.](ddp33003){#DDP330F3}

###### 

The 78 probe sets corresponding to 53 genes drawn from the 99 probe sets list generated from the intersection between the Illumina and Affymetrix platforms of those genes that were the most consistently expressed within the YRI population and the CEU population, respectively, in both parents and in children

       RefSeq               Common      Illumina Human V6 arrays   Affymetrix U133A array                                                                                         
  ---- -------------------- ----------- -------------------------- ------------------------ ------------------ ---------- ------------------ -------------------- --------------- ------------------
  1    NM_000462            UBE3A       GI_19718761-A              1.811                    2.87E−46           1.399      7.06E−23           211575_s\_at         1.0903921       2.75E−02
  2    NM_000516            GNAS        GI_18426899-A              1.215                    2.05E−13           1.174      2.87E−05           217673_x\_at         1.0949674       6.97E−03
  3    **NM**\_**000553**   **WRN**     **GI**\_**19924171-S**     **1.94**                 **1.18E**−**50**   **1.54**   **5.25E**−**28**   **205667**\_**at**   **1.1819617**   **6.51E**−**03**
  4    NM_000938            POLR2B      GI_4505940-S               1.621                    1.10E−38           1.431      3.83E−19           201803_at            1.0732888       3.46E−02
  5    NM_000970            RPL6        GI_16753226-S              1.275                    2.41E−19           1.255      1.20E−14           200034_s\_at         1.1285841       1.90E−04
  6    NM_001001973         ATP5C1      GI_4885078-S               1.369                    5.61E−27           1.322      3.86E−17           214132_at            1.136883        3.77E−02
  7    NM_001020658         PUM1        GI_13491165-S              1.425                    5.04E−32           1.157      1.07E−06           201164_s\_at         1.132332        6.73E−04
  8    NM_001025105         CSNK1A1     GI_34147516-S              1.759                    3.37E−53           1.41       4.87E−20           206562_s\_at         1.2095745       1.88E−06
  9    NM_001037637         BTF3        GI_29126237-S              1.319                    1.10E−27           1.343      9.34E−18           208517_x\_at         1.1164298       9.27E−04
  10   NM_001037637         BTF3                                                                                                             211939_x\_at         1.0701255       4.22E−02
  11   NM_001037637         BTF3                                                                                                             214800_x\_at         1.1117729       4.48E−02
  12   NM_001253            CDC5L       GI_16357499-S              1.615                    4.73E−41           1.401      1.71E−21           209055_s\_at         1.2033471       3.16E−03
  13   NM_001253            CDC5L                                                                                                            209056_s\_at         1.1000586       3.90E−02
  14   NM_001402            EEF1A1      GI_25453469-S              1.185                    1.28E−17           1.129      1.14E−06           204892_x\_at         1.0640733       4.48E−02
  15   NM_001402            EEF1A1                                                                                                           206559_x\_at         1.0533731       3.46E−02
  16   NM_001402            EEF1A1                                                                                                           213477_x\_at         1.0572026       2.50E−02
  17   NM_001655            ARCN1       GI_21626463-S              1.579                    4.07E−42           1.304      4.26E−14           201176_s\_at         1.1239741       2.60E−03
  18   NM_001686            ATP5B       GI_32189393-S              1.403                    5.41E−29           1.412      1.86E−22           201322_at            1.1220461       5.21E−03
  19   NM_002136            HNRNPA1     GI_4504444-A               1.43                     1.26E−34           1.297      4.39E−18           201054_at            1.1059377       1.13E−03
  20   NM_002136            HNRNPA1                                                                                                          201055_s\_at         1.1102453       2.44E−02
  21   NM_002136            HNRNPA1                                                                                                          200016_x\_at         1.1229433       9.27E−04
  22   NM_002136            HNRNPA1                                                                                                          214280_x\_at         1.0547829       2.69E−02
  23   NM_002136            HNRNPA1                                                                                                          213356_x\_at         1.1725581       5.58E−03
  24   NM_002568            PABPC1      GI_4505574-S               1.248                    6.13E−18           1.188      1.31E−08           215157_x\_at         1.0570977       3.90E−02
  25   NM_002734            PRKAR1A     GI_33636720-S              1.338                    2.02E−26           1.174      2.32E−07           200604_s\_at         1.2528985       6.87E−03
  26   NM_002799            PSMB7       GI_23110926-S              1.252                    5.01E−10           1.361      9.07E−13           200786_at            1.0921669       3.01E−02
  27   NM_003074            SMARCC1     GI_21237801-S              1.39                     3.16E−27           1.305      3.01E−16           201072_s\_at         1.2108523       6.51E−03
  28   NM_003074            SMARCC1                                                                                                          201073_s\_at         1.1169357       1.44E−02
  29   NM_003074            SMARCC1                                                                                                          201074_at            1.1553272       1.68E−03
  30   NM_003074            SMARCC1                                                                                                          201075_s\_at         1.3044553       7.31E−04
  31   NM_003079            SMARCE1     GI_21264354-S              1.514                    1.96E−36           1.469      1.39E−22           211988_at            1.1161661       1.52E−02
  32   NM_003079            SMARCE1                                                                                                          211989_at            1.1394086       5.06E−05
  33   NM_003188            MAP3K7      GI_21735565-A              1.519                    1.70E−40           1.283      2.45E−18           206854_s\_at         1.1580838       6.36E−03
  34   NM_003188            MAP3K7                                                                                                           211536_x\_at         1.2212324       2.60E−03
  35   NM_003188            MAP3K7                                                                                                           211537_x\_at         1.2388926       1.68E−03
  36   NM_003292            TPR         GI_4507658-S               1.163                    2.08E−08           1.245      7.99E−12           201731_s\_at         1.155994        1.33E−05
  37   NM_003292            TPR                                                                                                              215220_s\_at         1.157391        9.27E−04
  38   NM_003463            PTP4A1      GI_17986281-S              1.772                    1.61E−49           1.423      2.23E−19           200730_s\_at         1.4767935       1.21E−05
  39   NM_003463            PTP4A1                                                                                                           200731_s\_at         1.3223011       1.32E−06
  40   NM_003463            PTP4A1                                                                                                           200732_s\_at         1.4044188       7.38E−10
  41   NM_003463            PTP4A1                                                                                                           200733_s\_at         1.1612434       2.42E−03
  42   NM_003910            BUD31       GI_32171174-S              1.552                    5.62E−39           1.487      1.90E−23           205690_s\_at         1.2200912       3.01E−04
  43   NM_004500            HNRNPC      GI_14110430-A              1.243                    1.69E−18           1.317      8.75E−18           216559_x\_at         1.4150078       3.95E−04
  44   NM_004500            HNRNPC                                                                                                           221919_at            1.3094529       1.21E−05
  45   NM_004500            HNRNPC                                                                                                           200751_s\_at         1.2383838       3.26E−06
  46   NM_004559            YBX1        GI_34098945-S              1.372                    3.29E−29           1.206      1.88E−10           208628_s\_at         1.0818504       4.22E−02
  47   NM_005022            PFN1        GI_16753213-S              1.194                    5.56E−14           1.245      1.92E−15           200634_at            1.1045147       4.77E−02
  48   NM_005594            NACA        GI_40254826-S              1.218                    2.56E−17           1.117      0.000161           208635_x\_at         1.0518152       2.50E−02
  49   NM_005778            RBM5        GI_5032030-S               1.288                    1.78E−19           1.209      2.07E−08           209936_at            1.1065431       2.62E−02
  50   NM_005791            MPHOSPH10   GI_31317304-S              1.627                    2.44E−32           1.576      3.59E−27           212885_at            1.1840862       1.29E−04
  51   NM_005973            PRCC        GI_40807446-S              1.568                    2.08E−42           1.325      5.83E−13           208938_at            1.1030719       1.33E−02
  52   NM_006627            POP4        GI_5729985-S               1.344                    1.35E−21           1.313      7.84E−17           202868_s\_at         1.0857801       4.23E−02
  53   NM_006628            ARPP-19     GI_19923363-S              1.568                    9.80E−38           1.342      3.23E−17           221483_s\_at         1.1252328       1.47E−02
  54   NM_006766            MYST3       GI_5803097-S               1.196                    1.23E−10           1.327      1.76E−15           216361_s\_at         1.0696214       2.00E−02
  55   NM_006805            HNRPA0      GI_14110425-S              1.293                    2.06E−13           1.373      1.90E−14           212626_x\_at         1.1094681       1.74E−02
  56   NM_006805            HNRPA0                                                                                                           214737_x\_at         1.1395135       3.40E−02
  57   NM_006838            METAP2      GI_27597083-S              1.582                    2.78E−36           1.364      7.26E−22           213899_at            1.1602293       2.20E−03
  58   NM_007062            PWP1        GI_5902033-S               1.533                    2.72E−36           1.411      1.30E−21           201608_s\_at         1.1194986       4.62E−03
  59   NM_007363            NONO        GI_34932413-S              1.192                    1.27E−11           1.218      1.28E−15           208698_s\_at         1.2085309       4.91E−03
  60   NM_007363            NONO                                                                                                             210470_x\_at         1.1560814       1.66E−02
  61   NM_012245            SNW1        GI_18860912-S              1.371                    2.14E−25           1.334      9.62E−16           215424_s\_at         1.168398        7.76E−03
  62   NM_014077            FAM32A      GI_7661695-S               1.315                    3.44E−24           1.24       2.80E−12           201863_at            1.0926882       2.40E−03
  63   NM_014607            UBXD2       GI_34222095-S              1.254                    2.64E−13           1.377      9.30E−19           212006_at            1.1622256       7.76E−03
  64   NM_014607            UBXD2                                                                                                            212008_at            1.1967869       4.48E−02
  65   NM_014691            AQR         GI_38788371-S              1.603                    3.04E−40           1.573      3.89E−32           212584_at            1.1355405       1.79E−03
  66   NM_014827            ZC3H11A     GI_7662231-S               1.297                    3.78E−20           1.207      1.40E−08           205787_x\_at         1.1662422       1.14E−04
  67   NM_014827            ZC3H11A                                                                                                          205788_s\_at         1.1195558       9.27E−04
  68   NM_015138            RTF1        GI_34222098-S              1.51                     1.25E−39           1.29       6.64E−18           212301_at            1.0887809       2.85E−02
  69   NM_015235            CSTF2T      GI_14149674-S              1.448                    1.86E−34           1.258      2.01E−12           212905_at            1.1704319       5.45E−03
  70   NM_016167            NOL7        GI_15743546-S              1.485                    8.80E−28           1.55       3.28E−29           202882_x\_at         1.0945534       1.13E−02
  71   NM_016604            JMJD1B      GI_38372908-S              1.406                    3.16E−29           1.182      3.45E−09           210878_s\_at         1.1330327       2.62E−02
  72   NM_016648            LARP7       GI_7705400-S               1.707                    2.80E−45           1.462      1.83E−28           212785_s\_at         1.1426488       6.83E−03
  73   NM_017426            NUP54       GI_26051236-S              1.819                    1.53E−48           1.404      4.29E−21           218256_s\_at         1.144816        2.16E−03
  74   NM_017730            QRICH1      GI_38570096-S              1.644                    1.06E−46           1.433      3.29E−23           209174_s\_at         1.0828506       1.54E−02
  75   NM_018011            ARGLU1      GI_8922258-S               1.418                    1.05E−25           1.349      6.49E−17           218067_s\_at         1.1376716       4.12E−02
  76   NM_021188            ZNF410      GI_10863994-S              1.507                    5.98E−40           1.233      4.13E−12           202010_s\_at         1.0814468       1.49E−02
  77   NM_024844            NUP85       GI_34147385-S              1.543                    1.16E−29           1.498      9.33E−23           218014_at            1.2494535       6.29E−05
  78   NM_052940            LRRC42      GI_31543202-S              1.75                     2.18E−45           1.377      2.74E−19           215084_s\_at         1.0861734       3.25E−02

WRN is given in bold.

###### 

The 51 Functions identified by the IPA package for the cross-platform 78 Probes sets differentially expressed between CEU and YRI Trios

       Function                     Function annotation                             *P*-value      Molecules
  ---- ---------------------------- ----------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    Processing                   processing of mRNA                              2.70E−06       CDC5L, CSTF2T, HNRNPA0, NONO, PABPC1, SNW1
  2    **Cross-link repair**        **cross-link repair of DNA**                    **1.26E−04**   **CDC5L, WRN (includes EG:7486)**
  3    Biosynthesis                 biosynthesis of ADP                             1.88E−04       ATP5B, ATP5C1
  4    Binding                      binding of Gal4p binding site                   3.49E−04       SMARCC1, SMARCE1
  5    Packaging                    packaging of DNA                                4.48E−04       MYST3, SMARCC1
  6    Disruption                   disruption of nucleosomes                       6.81E−04       SMARCC1, SMARCE1
  7    **Transactivation**          **transactivation of HIV-1**                    **6.81E−04**   **SNW1, WRN (includes EG:7486)**
  8    **Transcription**            **transcription**                               **8.08E−04**   **BTF3 (includes EG:689), BUD31 (includes EG:8896), CDC5L, MAP3K7, MYST3, PFN1, POLR2B, PRKAR1A, PWP1, RPL6, SMARCC1, SMARCE1, SNW1, WRN (includes EG:7486), YBX1**
  9    Modification                 modification of RNA                             8.26E−04       HNRNPC, NONO, PABPC1, RBM5
  10   Expression                   expression of DNA                               8.99E−04       BTF3 (includes EG:689), BUD31 (includes EG:8896), CDC5L, MYST3, PFN1, POLR2B, PRKAR1A, RPL6, SMARCC1, SMARCE1, SNW1, YBX1
  11   **Immortalization**          **immortalization of fibroblast cell lines**    **9.62E−04**   **PRKAR1A, WRN (includes EG:7486)**
  12   **Transactivation**          **transactivation of HIV**                      **1.29E−03**   **SNW1, WRN (includes EG:7486)**
  13   Catabolism                   catabolism of ATP                               1.66E−03       ATP5B, ATP5C1
  14   Polyadenylation              polyadenylation of mRNA                         1.66E−03       CSTF2T, PABPC1
  15   Cell division process        cell division process of oocytes                2.31E−03       GNAS, TPR
  16   Cytostasis                   cytostasis of cell lines                        2.66E−03       METAP2 (includes EG:10988), PRKAR1A, SMARCE1, UBE3A
  17   Moiety attachment            moiety attachment of mRNA                       2.79E−03       CSTF2T, PABPC1
  18   Contact growth inhibition    contact growth inhibition of cell lines         2.94E−03       METAP2 (includes EG:10988), PRKAR1A, SMARCE1
  19   Cell division process        cell division process of female germ cells      3.60E−03       GNAS, TPR
  20   Metabolism                   metabolism of ATP                               4.19E−03       ATP5B, ATP5C1
  21   Cell death                   cell death of tumor cell lines                  4.42E−03       CSNK1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5, SMARCC1, SMARCE1, YBX1
  22   Metabolic process            metabolic process of ATP                        4.50E−03       ATP5B, ATP5C1
  23   Contact growth inhibition    contact growth inhibition of eukaryotic cells   5.05E−03       METAP2 (includes EG:10988), PRKAR1A, SMARCE1
  24   Apoptosis                    apoptosis of tumor cell lines                   5.73E−03       CSNK1A1, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5, SMARCC1, SMARCE1, YBX1
  25   Processing                   processing of RNA                               5.81E−03       HNRNPC, NONO, RBM5
  26   Contact growth inhibition    contact growth inhibition                       6.81E−03       METAP2 (includes EG:10988), PRKAR1A, SMARCE1
  27   Cell death                   cell death of cell lines                        9.49E−03       CSNK1A1, EEF1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5, SMARCC1, SMARCE1, YBX1
  28   Cell division process        cell division process of germ cells             9.94E−03       GNAS, TPR
  29   **Activation**               **activation of HIV-1**                         **1.14E−02**   **SNW1, WRN (includes EG:7486)**
  30   Cell division process        cell division process of gonadal cells          1.14E−02       GNAS, TPR
  31   **Transactivation**          **transactivation of Retroviridae**             **1.18E−02**   **SNW1, WRN (includes EG:7486)**
  32   Contact growth inhibition    contact growth inhibition of tumor cell lines   1.23E−02       PRKAR1A, SMARCE1
  33   **Immortalization**          **immortalization of cells**                    **1.28E−02**   **PRKAR1A, WRN (includes EG:7486)**
  34   Splicing                     splicing of mRNA                                1.34E−02       CDC5L, SNW1
  35   **Transcription**            **transcription of gene**                       **1.94E−02**   **BTF3 (includes EG:689), MAP3K7, MYST3, POLR2B, WRN (includes EG:7486)**
  36   **Transactivation**          **transactivation of virus**                    **2.02E−02**   **SNW1, WRN (includes EG:7486)**
  37   Papillary carcinoma          papillary carcinoma                             2.21E−02       PRKAR1A, TPR
  38   Development                  development of animal                           2.33E−02       GNAS, HNRNPC, MYST3, PRKAR1A, YBX1
  39   **Expression**               **expression of gene**                          **2.35E−02**   **BTF3 (includes EG:689), MAP3K7, MYST3, POLR2B, WRN (includes EG:7486)**
  40   Developmental process        developmental process of leukemia cell lines    2.56E−02       JMJD1B, MYST3, PRKAR1A
  41   Splicing                     splicing of RNA                                 2.69E−02       HNRNPC, NONO
  42   **Colony formation**         **colony formation of fibroblast cell lines**   **2.90E−02**   **PRCC, WRN (includes EG:7486)**
  43   Developmental process        developmental process of animal                 2.90E−02       GNAS, HNRNPC, METAP2 (includes EG:10988), MYST3, PRKAR1A, YBX1
  44   Bipolar affective disorder   bipolar affective disorder                      2.98E−02       ATP5C1, GNAS, PRKAR1A
  45   **Developmental process**    **developmental process of organism**           **3.17E−02**   **GNAS, HNRNPC, METAP2 (includes EG:10988), MYST3, PRKAR1A, WRN (includes EG:7486), YBX1**
  46   **Apoptosis**                **apoptosis of eukaryotic cells**               **3.53E−02**   **CSNK1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5, SMARCC1, SMARCE1, WRN (includes EG:7486), YBX1**
  47   **Primary tumor**            **primary tumor**                               **3.97E−02**   **EEF1A1, GNAS, HNRNPA1, LARP7 (includes EG:51574), METAP2 (includes EG:10988), PFN1, PRCC, PRKAR1A, TPR, UBE3A, WRN (includes EG:7486)**
  48   Synthesis                    synthesis of protein                            4.21E−02       EEF1A1, METAP2 (includes EG:10988), NACA, RPL6
  49   Tumorigenesis                tumorigenesis of tumor cell lines               4.75E−02       GNAS, PRKAR1A
  50   **Cell death**               **cell death of eukaryotic cells**              **4.77E−02**   **CSNK1A1, EEF1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5, SMARCC1, SMARCE1, WRN (includes EG:7486), YBX1**
  51   Gastric carcinoma            gastric carcinoma                               4.84E−02       LARP7 (includes EG:51574), PRCC

Bold values indicate biological functions with WRN enrichment.

###### 

The top 20 Pearson correlation coefficients (*R*^2^), *F*-statistic and *P*-values of WRN (dependent variable) mRNA expression in a pairwise manner to all 78 probe sets cross-platform validated with ACOO differential expression

  Illumina Human V6 arrays                                                                            
  -------------------------- --------------- -------------- ------------ ------- ------- ------------ -------
  1                          GI_19924171-S   NM_000553      **WRN**      1.000   1.000   5.15E + 33   \<2.2
  2                          GI_19718761-A   NM_000462      UBE3A        0.837   0.836   1329         \<2.2
  3                          GI_38570096-S   NM_017730      QRICH1       0.809   0.808   1097         \<2.2
  4                          GI_7705400-S    NM_016648      LARP7        0.790   0.790   976          \<2.2
  5                          GI_34147516-S   NM_001025105   CSNK1A1      0.782   0.781   927.1        \<2.2
  6                          GI_21735565-A   NM_003188      MAP3K7       0.780   0.779   915.8        \<2.2
  7                          GI_26051236-S   NM_017426      **NUP54**    0.767   0.766   853.7        \<2.2
  8                          GI_27597083-S   NM_006838      METAP2       0.763   0.763   835.6        \<2.2
  9                          GI_34222098-S   NM_015138      RTF1         0.763   0.762   833.3        \<2.2
  10                         GI_31543202-S   NM_052940      LRRC42       0.761   0.760   826.3        \<2.2
  11                         GI_5902033-S    NM_007062      **PWP1**     0.731   0.730   704.2        \<2.2
  12                         GI_38788371-S   NM_014691      AQR          0.724   0.723   678.4        \<2.2
  13                         GI_21626463-S   NM_001655      **ARCN1**    0.721   0.720   669          \<2.2
  14                         GI_16357499-S   NM_001253      **CDC5L**    0.719   0.718   661.8        \<2.2
  15                         GI_10863994-S   NM_021188      **ZNF410**   0.715   0.714   648.4        \<2.2
  16                         GI_4505940-S    NM_000938      **POLR2B**   0.708   0.707   62808        \<2.2
  17                         GI_31317304-S   NM_005791      MPHOSPH10    0.705   0.704   618.4        \<2.2
  18                         GI_13491165-S   NM_001020658   **PUM1**     0.696   0.695   593.5        \<2.2
  19                         GI_17986281-S   NM_003463      PTP4A1       0.695   0.694   590.9        \<2.2
  20                         GI_19923363-S   NM_006628      ARPP-19      0.690   0.689   577.2        \<2.2
  21                         GI_8922258-S    NM_018011      ARGLU1       0.690   0.689   57607        \<2.2

The eight boldfaced genes are part of the final immortalization network.

###### 

The 24 immortalization probe set Ids and ACOO expression differences in *P*-values for SekWon *et al*.\'s primary LBC data set (Affymetrix.GeneChip.HG-U133_Plus_2), Yelensky *et al*.\'s (Affymetrix.GeneChip.HG-U133A) and Stranger *et al*.\'s (Illumina WGA-6) immortalized LBC data sets

  Gene symbol   EBV immortalized B cells   Non-immortalized B cells                                                                                                         
  ------------- -------------------------- --------------------------- -------------- --------------------------- ---------- -------------- ------------------------------- ----------
  ARCN1         GI_21626463-S              1.5                         5.84E−55       201176_s\_at                1.1        1.67E−03       No significant difference       
  ATP5B         GI_32189393-S              1.4                         1.38E−48       201322_at                   1.1        2.77E−03       No significant difference       
  BAT1          GI_45580710-I              1.2                         3.13E−21       200041_s\_at                1.2        1.27E−05       1.5                             1.67E−03
                                                                                      212384_at                   1.2        2.10E−02       1.9                             1.66E−03
  CDC5L         GI_16357499-S              1.5                         2.48E−61       209055_s\_at                1.2        1.92E−03       2.3                             1.83E−05
                                                                                      209056_s\_at                1.1        2.60E−02       1.8                             1.74E−03
  DNAJA1        GI_4504510-S               1.8                         4.77E−55       200880_at                   1.1        1.67E−02       2.4                             2.68E−04
                                                                                      200881_s\_at                1.2        2.91E−04       4.4                             3.11E−10
  EXO1          GI_39995067-I              1.04                        4.04E−05       204603_at                   1.2        2.57E−05       No significant difference       
                GI_39995068-A              1.8                         1.04E−59                                                                                             
  FEN1          GI_19718776-S              1.8                         1.64E−55       204768_s\_at                1.4        2.20E−04       1.3                             5.06E−03
  JMJD1B        GI_38372908-S              1.3                         3.65E−37       210878_s\_at                           1.69E−02       No significant difference       
  NOL7          GI_15743546-S              1.5                         8.37E−55       202882_x\_at                1.1        6.93E−03       1.3                             2.06E−02
  NUP54         GI_26051236-S              1.6                         6.19E−65       218256_s\_at                1.1        1.22E−03       No significant difference       
  NUP62         GI_34335245-A              1.4                         4.41E−33       207740_s\_at                1.2        2.74E−02       1.3                             2.65E−02
  PFN1          GI_16753213-S              1.2                         5.76E−25       200634_at                   1.1        3.06E−02       No significant difference       
  PLRG1         GI_4505894-S               1.5                         3.68E−53       225194_at                   No Probe   1.4            2.06E−02                        
  POLR1A^a^     GI_7661685-S               1.3                         1.66E−09       222704_at                   No Probe   1.2            1.34E−03                        
  POLR2B        GI_4505940-S               1.5                         3.80E−58       201803_at                   1.1        2.25E−02       No significant difference       
  PRCC          GI_40807446-S              1.5                         1.14E−54       208938_at                   1.1        7.89E−03       No significant difference       
  PSME3         GI_30410793-A              1.8                         2.07E−45       200987_x\_at                1.2        3.51E−03       1.6                             2.94E−05
                                                                                      209853_s\_at                1.2        2.51E−03       1.6                             1.13E−05
  PUM1          GI_13491165-S              1.3                         1.10E−37       201164_s\_at                1.1        3.39E−04       No significant difference       
  PWP1          GI_5902033-S               1.5                         5.68E−58       201608_s\_at                1.1        2.51E−03       No significant difference       
  SFRS2         GI_4506898-S               1.9                         1.45E−62       200753_x\_at                1.2        1.22E−03       1.4                             2.06E−02
  VCP           GI_7669552-S               1.3                         1.78E−17       208649_s\_at                1.2        3.47E−04       1.3                             2.12E−02
  **WRN**       **GI_19924171-S**          **1.8**                     **1.36E−73**   **205667_at**               **1.2**    **3.53E−03**   **No significant difference**   
  ZNF410        GI_10863994-S              1.4                         1.67E−51       202010_s\_at                1.1        9.10E−03       No significant difference       
  ZNF512B       GI_34013527-S              No significant difference   55872_at       No significant difference   1.2        3.86E−02                                       

Bold values indicate WRN gene significant difference across all three platforms.

^a^Gene with population specific eQTL.

Identification of ACOO immortalization sensitive genes {#s2c}
------------------------------------------------------

To further explore which subset of the COO differentially expressed genes is specific to ACOO but not immortalization and specific to differences in the immortalization process with respect to ACOO, the results above were contrasted to an expression study of non-immortalized lymphoid cells harvested from the peripheral blood from AA and CA children. Figure [4](#DDP330F4){ref-type="fig"} depicts a Venn diagram of the 78 significantly differentially expressed probe sets across platforms (Illumina and Affymetrix) between the immortalized CEU/YRI cells. Of those, 64 probe sets (82%) were confirmed to be significantly different between the AA and CA children populations. This left 14 probe sets (including WRN) that were differentially expressed across the CEU and YRI in the immortalized cell experiments.

![Twelve of the 14 probe sets identified in the Venn diagram with immortalized cell-specific differential expression (circled in Venn diagram), mapped to 12 independent genes in Ingenuity Pathway program to construct the 'immortalization network\'. The 12 independent genes are depicted in red. POLR1A which has an heritable eQTL in the YRI population with significant differential expression by ACOO is in green. The additional genes with ACOO significantly different expression but are not immortalization specific are in yellow.](ddp33004){#DDP330F4}

An EBV immortalization gene network {#s2d}
-----------------------------------

The 14 probe sets that are significantly different between CEU and YRI immortalized cells that were not identified in non-immortalized lymphoblast cells (LCs) were mapped into Ingenuity\'s (IPA) package (Ingenuity® Systems, [www.ingenuity.com](www.ingenuity.com)) to determine which networks were enriched with these genes. Twelve of the 14 probe sets were mapped into IPA identifying 12 genes (two were unmapped ESTs) ARCN1, ATP5B, JMJD1B, NOL7, NUP54, PFN1, POLR2B, PRCC, PUM1, PWP1, WRN, ZNF410. The genes clustered into three significantly overrepresented/enriched networks with 10 genes mapped into the top-scoring network of DNA replication, recombination and repair with a *P*-value of 10^−7^. JMJD18 and PUM1 mapped separately to Networks 2 and 3. The 10 genes from Network 1 were exported into Ingenuity\'s Pathway editor to build a combined 'Immortalization Network' that includes JMJD18 and PUM1 (colored red in Fig. [4](#DDP330F4){ref-type="fig"}). There were several genes enriched in the '*Immortalization Network*' that were not part of the original 14 gene list. Subsequent to finding the marked network enrichment score, we relaxed the cutoffs in three ways, intra-population consistency criterion, *P*-value cutoff and multiple test correction (see Materials and Methods for more detail) in determining the statistical inference of the additional genes in the Immortalization Network, for the Illumina Platform only. By relaxing the aggressive filtering (of samples and genes) originally performed to increase specificity across the noisy and different expression platforms, an additional 11 genes (NUP62, BAT1, PSME3, SFRS2, PLRG1, CDC5L, EXO1, FEN1, DNAJA1, VCP and ZNF512B) were identified that have an ACOO-significant expression difference (Table [4](#DDP330TB4){ref-type="table"}) in the Immortalization Network (colored yellow in Fig. [4](#DDP330F4){ref-type="fig"}).

Continent of origin (COO) eQTLs within the associated immortalization pathway {#s2e}
-----------------------------------------------------------------------------

We determined whether any of the genes in the '*Immortalization Network*' which had ACOO significant expression difference across the two immortalized and control data sets manifested heritable eQTL differences between CEU and YRI by using the public SNP data from NCBI build 36 (dbSNP b126) (<http://ftp.hapmap.org/genotypes/2008-10_phaseII/>). There was one gene, POLR1A (colored green in Fig. [4](#DDP330F4){ref-type="fig"}), with expression in the YRI cohort founders (60 samples) that associated with SNP rs12124 in a *cis* eQTL (--log10 *P*-value = 5.77 × 10^−9^). POLR1A also has ACOO discordant expression across all three data sets. This eQTL finding is consistent with a previous report by Stranger *et al*. (data not shown).

DISCUSSION {#s3}
==========

The YRI is one of the native sub-Saharan populations suffering from the childhood cancer pandemic BL caused by the EBV. The International HapMap Project harvested peripheral blood lymphoblasts from the YRI trios and then transformed them into immortalized cells using EBV *in vitro*. This raised the question of the degree to which the previously reported expression differences are due to laboratory technique, measurement platform difference, laboratory-specific variation in EBV-driven cell immortalization or COO-specific responses to EBV infection and immortalization. To explore this question we tailored the approach outlined in Figure [1](#DDP330F1){ref-type="fig"}. This analysis led to the identification of an immortalization network characterizing the expression differences specific to the immortalization process of the CEU and YRI samples across three independent studies ([@DDP330C4],[@DDP330C14],[@DDP330C15]) and distinct from a fourth independent study of ACOO differences in non-immortalized cells of AA and CA cohorts ([@DDP330C16]). Of note, one of the genes in this network, WRN, a gene mutated in Werner Syndrome (WS), a recessive genetic disorder associated with a complex premature ageing phenotype, has been shown to modulate the efficiency of EBV immortalization of LC lines ([@DDP330C18],[@DDP330C19]), possibly through its role in the stabilization of telomeres and telomerase and the immortalized genome ([@DDP330C20],[@DDP330C21]). Likewise, the expression of WRN (and the other genes in the immortalization network) is highly correlated with EBV titer (Fig. [2](#DDP330F2){ref-type="fig"}). Sixteen (80%) of the top 20 genes most correlated with WRN and sixteen (80%) of its twenty most correlated genes grouped into one biological functions network associated with gene expression, infection mechanism and cancer here termed *'Viral infection network*'. Seven of the top 20 genes of the viral infection network are part of the final 12 genes that framed the immortalization network. At the center of this network are transcription factors MYC and P53. The MYC gene recently reported by Faumant *et al*. ([@DDP330C22]) was to be one of the two 'master' transcriptional systems activated in latency III program of EBV immortalization of B-cells. Among their reported major players in the EBV immortalization process are EXO1 and FEN1 which both directly bind to WRN and are significantly different and enriched in our reported immortalization network. In addition, p53 is among the genes in the viral infection network and was reported recently by Yi *et al*. ([@DDP330C23]) to have its transcriptional and apoptotic activities modulated by the EBV protein EBNA3C latent antigen essential for *in vitro* B-cell immortalization. This analysis does not rule out the possibility that all the observed COO differences are a function of a batch effect of the different times, techniques and laboratories involved in the immortalization process of the different HapMap populations even with observed differences in three sets of experiments. However, POLR1A\'s significantly up-regulated expression and the specific eQTL within the YRI founders may play a role in this population\'s increased sensitivity to EBV infection. Albeit circumstantial evidence, recently published by Michiels *et al*. ([@DDP330C24]) supports a possible role of POLR1A as a marker for head-and-neck cancers. Additionally, research by Shiratori *et al*. ([@DDP330C25]) reported that in WS fibroblasts, the WRN gene promotes rRNA transcription as a component of an RNA polymerase I (RPI)-associated complex, of which POLR1A is one of the core subunits ([@DDP330C26]). The Shiratori *et al*.\'s study identified decreased levels of rRNA transcription compared with wild-type cells as a measurable marker for characterizing the premature aging of WS. They further showed how fibroblast cells in the presence of wild-type WRN increased rRNA levels and cell proliferation. Although further studies are required to elucidate POLR1A\'s role in EBV-transformed B-cell, our findings shed light on POLR1A as a component of the EBV *in vitro* cell immortalization process with a possible ACOO hereditary signature. The findings presented here are consistent with the yet unproven hypothesis that these *in vitro* results echo population health; that is, lymphoblastoid cell lines sensitivity to EBV immortalization may mirror the EBV infection pandemic in Central Africa. The aforementioned data are presented as initial evidence of a set of genes that differ in expression by ACOO and among them a subset of genes that is environmentally sensitive to EBV in healthy individuals. Further studies are required to evaluate this hypothesis and measurements in individuals with different COO during *in vivo* EBV infection might be illuminating in this regard.

MATERIALS AND METHODS {#s4}
=====================

Normalization {#s4a}
-------------

In the initial analysis of the Illumina Human V6 arrays used by Stranger *et al*. ([@DDP330C4]) and the Affymetrix Human Focus arrays used by Storey *et al*. ([@DDP330C14]), array probe set intensities that were \<0.01 were set to 0.01. For each individual array, all probe sets were divided by the 50th percentile of all probes sets on that array and then each gene was divided by the median of its measurements across all arrays. For the U133 Array Set HG-U133A and the HG-U133-Plus-2 arrays, we applied GCRMA normalization. The expression arrays used to determine eQTLs were normalized as described in the Bioconductor program ([@DDP330C27]) GGtools 3.0 created by Vince Carey ([@DDP330C28]).

Noise reduction in Stranger *et al*.\'s data set {#s4b}
------------------------------------------------

We intentionally pursued a highly conservative analysis to maximize specificity. Each population was filtered to include only genes that have a 100% detection rate across all *in-vitro* transcriptions (IVTs) to be compared. For the first data set ([@DDP330C4]): out of the 47 293 probe sets on each array \[compared between the CEU (60 samples) and YRI (60 samples) parents and children (30 samples each) groups\], only 4640 probes for CEU~p~ and YRI~p~ and 4839 probes for CEU~c~ and YRI~c~ populations were detected at 100% across all IVTs. To determine the IVT replication outliers, principal component analysis of the 100% detected gene list was used. An outlier was defined as any IVT that was not within the same quarter as the other replicates in the four quarters from PC1 (*x*-axis) and PC2 (*y*-axis) ([Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp330/DC1)). There had to be at least three IVTs grouped for each cell line for inclusion in the analysis. The gene intensity variation across replicated IVTs within a population was filtered to include only those probes sets with a ± 0.5 standard deviation of the mean. This resulted in the following sets of *population-consistent* probe sets: YRI~p~ 3121 probe sets, CEU~p~ 2759 probe sets, YRI~c~ 1640 probe sets and CEU~c~ with 1520 probe sets whose combined expression ranges were within a one standard deviation band spanning the population mean. Differentially expressed probe sets were identified using one-way ANOVA (false discovery rate of 0.01, *t*-test with unequal variance and Bonferroni correction for multiple testing). We then obtained the intersection of the population-consistent probe sets across YRI~p~ and CEU~p~ identifying 1043 such probe sets. We compared the mean expression of the 1043 probe sets between CEU~p~ and YRI~p~ (*t*-test with *P*-value = 0.01 and Bonferroni correction), resulting in 958 probe sets that were significantly different between CEU~p~ and YRI~p~ populations. Within the CEU~c~ versus YRI~c~ populations, there were 607 shared probe sets that were population consistent in their respective populations. We compared the mean expression differences of 607 probe sets between CEU~c~ and YRI~c~ using *t*-test as previously described; this resulted in 568 probe sets that were significantly different between CEU~c~ and YRI~c~ populations. Of the above 958 and 568 differentially expressed probes, 228 probe sets were differentially expressed in both parent and child populations. When the same analysis was performed applying the same rigorous filtering on a smaller data set of eight CEU and eight YRI founder males, the only gene differentially expressed was WRN on the Affymetrix Human Focus Array ([@DDP330C14]).

The 228 probe sets' network analysis {#s4c}
------------------------------------

We used the Ingenuity Pathways Analysis program (IPA---Ingenuity® Systems, [www.ingenuity.com](www.ingenuity.com)) to analyze the set of differentially expressed probe sets. Of the 228 probe sets, we exclude 11 expressed sequence tags (ESTs), and the remaining 217 probe sets were mapped into IPA with 140 of the 217 probe sets specifically mapping into the functions/pathways by RefSeq accession numbers. With removal of redundant gene symbols, 101 genes in total enriched 269 functions and diseases annotations (FAs). Of the 269 FAs significantly enriched within the 228 probe list, we removed 237 enriched FAs that had less than three genes, *P*-values \>0.05 and/or redundant names, resulting in a final 32 FA categories enriched in the differentially expressed gene list comparing CEU and YRI samples. The 32 enriched FAs are comprised of 87 (86%) of the overall 101 genes annotated in FAs by the IPA package (Data not shown).

Viral titers {#s4d}
------------

Cell-line-specific viral titers were shared with us courtesy of David Altshuler and Roman Yelensky (Broad Institute, Cambridge, MA, USA). Relative EBV copy number was determined by the difference of CT method ([@DDP330C2]) and log-transformed. EBV measurements were obtained when cell-lines were first received from the Coriell Institute in 2005.

Cross platform validation of the 228 genes in Yelensky *et al*. affymetrix data set {#s4e}
-----------------------------------------------------------------------------------

The 228 genes identified with COO differential expression from Stranger *et al*. samples (Illumina platform) were validated across platforms using an independent study of the same samples from the CEU and YRI populations on the Affymetrix GeneChip Human Genome U133 Array Set HG-U133A ([@DDP330C15]). The initial 228-gene list mapped to 352 probe sets on the HG-U133A array by RefSeq accession number. Of the 228 genes that were significantly different on the Illumina platform between CEU and YRI, there were 78 probe sets of the same genes that were significantly different at a *P*-value cutoff of 0.05 with Benjamini--Hochberg multiple testing correction on the Affymetrix platform. The WRN gene was also among the genes that were significantly different on the Affymetrix platform, a finding that was confirmed in a third independent study of Storey *et al*.\'s data on the Affymetrix Human Focus Arrays.

Squared Pearson correlation coefficients (*R*^2^) {#s4f}
-------------------------------------------------

We preformed a liner regression analyses to determine the squared Pearson correlation coefficients (*R*^2^) and *P*-values of WRN (dependent variable) mRNA expression in a pairwise manner to all 78 probe sets cross-platform validated with ACOO differential expression. We reported the genes with an *R*^2^ cutoff of 0.7 or greater (Table [3](#DDP330TB3){ref-type="table"}).

Intersection of the immortalized cell gene list with the non-immortalized significantly different gene list {#s4g}
-----------------------------------------------------------------------------------------------------------

We used an in house unpublished data set of AA and CA samples consisting of 43 male and female children from 1 to 16 years of age. These samples were collected as control samples in an unrelated study of autism spectrum disorder (ASD). LCs were isolated and RNA extracted (without EBV immortalization) and hybridized to the Affymetrix U133plus2 array. The initial 228 gene list mapped to 352 probe sets on the U133plus2 array by RefSeq accession number. Statistical inference was determined using parametric test; variance assumed unequal Student\'s *t*-test, *P*-value cutoff 0.05, with Benjamini-Hochberg multiple test correction. Of the 524 across platform-intersected probes, 288 probe sets had significant difference between the AA and CA cohorts. We cross array (U133Pluse2 to U133A) matched the RefSeq numbers of the 288 probes yielding 299 probes for intersection across platforms. We intersected the 299 probe sets with the across platform confirmed 78 probe sets that have discordant expression between CEU and YRI trios.

Immortalization network enrichment {#s4h}
----------------------------------

Twelve of the 14 probe sets identified as immortalized cell specific were enriched in IPA and mapped to 12 independent genes (two were unmapped ESTs). The genes clustered into 3 networks with 10 genes mapped into the top network of DNA replication, recombination and repair with a *P*-value of 10^−27^. JMJD18 and PUM1 mapped separately to Networks 2 and 3. The 10 genes from Network 1 were exported into IPA editor to construct the '*Immortalization Network*' including JMJD18 and PUM1. To determine whether any of these additional genes have significant ACOO differential expression (subsequent to finding the marked network enrichment score), we relaxed the statistical inference cutoffs in three ways. First, we no longer filtered the genes to meet the intra-population consistency criterion. Second, we relaxed the *P*-value cutoff from 0.01 to 0.05 and, finally, we changed the multiple test correction to Benjamini--Hochberg from Bonferroni for statistical inference for the Illumina Platform only.

ACOO-specific eQTLs {#s4i}
-------------------

The eQTLs were determined using the Bioconductor program ([@DDP330C27]) GGtools 3.0 written by Vince Carey. Here we used only the founder population (60 parents) for the CEU and YRI cohorts. A relevant eQTL was only determined to be of interest when it was discordant for significance across the YRI and CEU populations. A significant *cis* eQTL is defined as having an SNP correlated to a gene\'s expression within 50 kb from the 5′ or 3′ end of the gene with a significant *P*-values less than or equal to --log10 10^−8^.

SUPPLEMENTARY MATERIAL {#s5}
======================

[Supplementary Material is available at *HMG* online](http://hmg.oxfordjournals.org/cgi/content/full/ddp330/DC1).
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